The US Food & Drug Administration (FDA) has approved the use of the botulinum neurotoxin Xeomin® (incobotulinumtoxinA) as a first-line treatment of blepharospasm in adults, as announced in a press release from Merz. Blepharospasm is a focal dystonia that causes muscles around the eyes to contract involuntarily. Individuals with blepharospasm may experience excessive blinking, light […]
We need your valuable input. Please consider participating in a brief, anonymous survey to help the Dystonia Medical Research Foundation better understand your experiences with botulinum neurotoxin injections. Individuals who are diagnosed with dystonia and receive treatment in the USA are welcome to participate. Click here to participate. Any questions, please contact us.